New addition to handle material transfer agreements
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Visiting attendees represented some of the top names in in the industry.
Sam McNeal, Ph.D., and Michael Sweeney have joined the Technology Ventures staff.
Networking, lab tours highlight first OMRF BioVenture Forum
Technology Ventures works to pair scientists with industry partners.